KRAS and non-small cell lung carcinoma: In this context, we selected cell models of EGFR and KRAS-mutant NSCLC to study combinations of NOA targets as an alternative strategy to overcome and prevent TKI resistance, exploring the differences in various models (e.g., EGFR-TKI-sensitive versus EGFR-resistant model) as summarized in Figure 8.